Protocol for a Multicentre Survey of Patients With Treatment Resistant

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Project aims to determine the number of individuals with treatment resistant hypertension and to define the characteristics of these patients and estimate disease frequency. The study will be a retrospective review of medical record data based upon de‐identified information and will require no patient contact.

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT03317951` - Investigation of a Novel Integrated Care Concept (NICC) for Patients Suffering From Chronic Cardiovascular Disease	N/A

NCT number	NCT03078244
Study type	Observational
Source	George Clinical Pty Ltd
Contact
Status	Completed
Phase	N/A
Start date	November 2016
Completion date	August 31, 2017

Protocol for a Multicentre Survey of Patients With Treatment Resistant Hypertension — SPIRIT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms